Semliki Forest virus infection is enhanced in Th1-prone SJL mice but not in Th2-prone BALB/c mice during Linomide-induced immunomodulation

Journal of Neuroimmunology

Volumn 132, Issue 1-2, 2002, Pages 83-92

  Peltoniemi, J ^a   Setala N ^a,b   Broberg, E ^a,b   Roytta M ^a   Hukkanen, V ^a,b   Salmi, A A ^a,b   Eralinna J P ^a,b,c  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Antigen presenting cells; Cytokines; Immunomodulation; Infection; Semliki Forest virus

Indexed keywords

CD11B ANTIGEN; CYTOKINE; GAMMA INTERFERON; GLYCOPROTEIN P 15095; INTERLEUKIN 12; PNU 212616; ROQUINIMEX;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; BRAIN; CELL POPULATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; IMMUNE RESPONSE; IMMUNOMODULATION; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; SEMLIKI FOREST ALPHAVIRUS; SPLEEN CELL; TARGET CELL; TH1 CELL; TH2 CELL; VIRUS INFECTION;

EID: 0036850491     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(02)00312-0     Document Type: Article

References (37)

1. Amor S., Scallan M.F., Morris M.M., Dyson H., Fazakerley J.K. Role of immune responses in protection and pathogenesis during Semliki Forest virus encephalitis. J. Gen. Virol. 77:1996;281-291.
2. Andersen O., Lycke J., Tollesson P.O., Svenningsson A., Runmarker B., Linde A.S., Astrom M., Gjorstrup P., Ekholm S. Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology. 47:1996;895-900.
3. Arad G., Katzenellenbogen M., Levy R., Slavin S., Kaempfer R. Linomide, an immunomodulator that inhibits Th1 cytokine gene expression. Int. Immunol. 8:1996;1603-1607.
4. Bai X.F., Shi F.D., Zhu J., Xiao B.G., Hedlund G., Link H. Linomide-induced suppression of experimental autoimmune neuritis is associated with down-regulated macrophage functions. J. Neuroimmunol. 76:1997;177-184.
5. Charles P.C., Weber K.S., Cipriani B., Brosnan C.F. Cytokine, chemokine and chemokine receptor mRNA expression in different strains of normal mice: implications for establishment of a Th1/Th2 bias. J. Neuroimmunol. 100:1999;64-73.
6. Dahlen E., Andersson M., Dawe K., Tellander A.C., Brunmark C., Bjork A., Hedlund G., Bai X.F., Shi F.D., Zhu J., Xiao B.G., Link H. Inhibition of autoimmune disease by the immunomodulator linomide correlates with the ability to activate macrophages. Autoimmunity. 32:2000;199-211.
7. Drescher K.M., Rivera Quinones C., Lucchinetti C.F., Rodriguez M. Failure of treatment with Linomide or oral myelin tolerization to ameliorate demyelination in a viral model of multiple sclerosis. J. Neuroimmunol. 88:1998;111-119.
8. Erälinna J.P., Soilu-Hänninen M., Röyttä M., Hukkanen V., Salmi A.A., Salonen R. Blood-brain barrier breakdown and increased intercellular adhesion molecule (ICAM-1/CD54) expression after Semliki Forest (A7) virus infection facilitates the development of experimental allergic encephalomyelitis. J. Neuroimmunol. 66:1996;103-114.
9. Erälinna J.P., Röyttä M., Hukkanen V., Zinhu D., Salmi A.A., Salonen R. Selective downregulation of Th1 response by Linomide reduces autoimmunity but increases susceptibility to viral infection in BALB/c and SJL mice. J. Neuroimmunol. 88:1998;165-176.
10. Fazakerley J.K., Webb H.E. Cyclosporine enhances virally induced T-cell-mediated demyelination. The effect of cyclosporine on a demyelinating virus infection. J. Neurol. Sci. 78:1987;35-50.
11. Gonzalo J.A., Gonzalez Garcia A., Kalland T., Hedlund G., Martinez C., Kroemer G. Linomide inhibits programmed cell death of peripheral T cells in vivo. Eur. J. Immunol. 24:1994;48-52.
12. Gran B., Tranquill L.R., Chen M., Bielekova B., Zhou W., Dhib Jalbut S., Martin R. Mechanisms of immunomodulation by glatiramer acetate. Neurology. 55:2000;1704-1714.
13. Gross D.J., Weiss L., Reibstein I., Hedlund G., Dahlen E., Rapoport M.J., Slavin S. The immunomodulator Linomide: role in treatment and prevention of autoimmune diabetes mellitus. Int. Immunopharmacol. 1:2001;1131-1139.
14. Guler M.L., Gorham J.D., Hsieh C.S., Mackey A.J., Steen R.G., Dietrich W.F., Murphy K.M. Genetic susceptibility to Leishmania: IL-12 responsiveness in TH1 cell development. Science. 271:1996;984-987.
15. Harandi A.M., Svennerholm B., Holmgren J., Eriksson K. Interleukin-12 (IL-12) and IL-18 are important in innate defense against genital herpes simplex virus type 2 infection in mice but are not required for the development of acquired gamma interferon-mediated protective immunity. J. Virol. 75:2001;6705-6709.
16. Hedlund G., Link H., Zhu J., Xiao B.G. Effects of Linomide on immune cells and cytokines inhibit autoimmune pathologies of the central and peripheral nervous system. Int. Immunopharmacol. 1:2001;1123-1130.
17. Kalland T. Regulation of natural killer progenitors. Studies with a novel immunomodulator with distinct effects at the precursor level. J. Immunol. 144:1990;4472-4476.
18. Karussis D.M., Lehmann D., Slavin S., Vourka Karussis U., Mizrachi Koll R., Ovadia H., Ben Nun A., Kalland T., Abramsky O. Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide. Ann. Neurol. 34:1993;654-660.
19. Karussis D.M., Lehmann D., Slavin S., Vourka Karussis U., Mizrachi Koll R., Ovadia H., Kalland T., Abramsky O. Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide). Proc. Natl. Acad. Sci. U. S. A. 90:1993;6400-6404.
20. Karussis D.M., Meiner Z., Lehmann D., Gomori J.M., Schwarz A., Linde A., Abramsky O. Treatment of secondary progressive multiple sclerosis with the immunomodulator Linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology. 47:1996;341-346.
21. Karussis D., Abramsky O., Rosenthal Y., Mizrachi Koll R., Ovadia H. Linomide downregulates autoimmunity through induction of TH2 cytokine production by lymphocytes. Immunol. Lett. 67:1999;203-208.
22. Leenen P.J., de Bruijn M.F., Voerman J.S., Campbell P.A., van Ewijk W. Markers of mouse macrophage development detected by monoclonal antibodies. J. Immunol. Methods. 174:1994;5-19.
23. Leenen P.J., Radosevic K., Voerman J.S., Salomon B., van Rooijen N., Klatzmann D., van Ewijk W. Heterogeneity of mouse spleen dendritic cells: in vivo phagocytic activity, expression of macrophage markers and subpopulation turnover. J. Immunol. 160:1998;2166-2173.
24. Lehmann D., Karussis D.M., Fluresco D., Mizrachi Koll R., Ovadia H., Shezen E., Kalland T., Abramsky O. Immunomodulation of autoimmunity by linomide: inhibition of antigen presentation through down regulation of macrophage activity in the model of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 74:1997;102-110.
25. Maples J.A. A method for the covalent attachment of cells to glass slides for use in immunohistochemical assays. Am. J. Clin. Pathol. 83:1985;356-363.
26. Metlay J.P., Witmer Pack M.D., Agger R., Crowley M.T., Lawless D., Steinman R.M. The distinct leukocyte integrins of mouse spleen dendritic cells as identified with new hamster monoclonal antibodies. J. Exp. Med. 171:1990;1753-1771.
27. Mokhtarian F., Shi Y., Zhu P.F., Grob D. Immune responses, and autoimmune outcome, during virus infection of the central nervous system. Cell. Immunol. 157:1994;195-210.
28. Mokhtarian F., Wesselingh S.L., Choi S., Maeda A., Griffin D.E., Sobel R.A., Grob D. Production and role of cytokines in the CNS of mice with acute viral encephalomyelitis. J. Neuroimmunol. 66:1996;11-22.
29. Morris M.M., Dyson H., Baker D., Harbige L.S., Fazakerley J.K., Amor S. Characterization of the cellular and cytokine response in the central nervous system following Semliki Forest virus infection. J. Neuroimmunol. 74:1997;185-197.
30. Noseworthy J.H., Wolinsky J.S., Lublin F.D., Whitaker J.N., Linde A., Gjorstrup P., Sullivan H.C. Linomide in relapsing and secondary progressive MS: Part I. Trial design and clinical results. North American Linomide Investigators. Neurology. 54:2000;1726-1733.
31. Oxenius A., Karrer U., Zinkernagel R.M., Hengartner H. IL-12 is not required for induction of type 1 cytokine responses in viral infections. J. Immunol. 162:1999;965-973.
32. Scallan M.F., Fazakerley J.K. Aurothiolates enhance the replication of Semliki Forest virus in the CNS and the exocrine pancreas. J. Neurovirology. 5:1999;392-400.
33. Schijns V.E., Haagmans B.L., Wierda C.M., Kruithof B., Heijnen I.A., Alber G., Horzinek M.C. Mice lacking IL-12 develop polarized Th1 cells during viral infection. J. Immunol. 160:1998;3958-3964.
34. Tan I.L., Lycklama a Nijeholt G.J., Polman C.H., Ader H.J., Barkhof F. Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials. Mult. Scler. 6:2000;99-104.
35. Wu L.X., Mäkelä M.J., Röyttä M., Salmi A. Effect of viral infection on experimental allergic encephalomyelitis in mice. J. Neuroimmunol. 18:1988;139-153.
36. Xing Z., Zganiacz A., Wang J., Divangahi M., Nawaz F. IL-12-independent Th1-type immune responses to respiratory viral infection: requirement of IL-18 for IFN-gamma release in the lung but not for the differentiation of viral-reactive Th1-type lymphocytes. J. Immunol. 164:2000;2575-2584.
37. Yasuda C.L., Al Sabbagh A., Oliveira E.C., Diaz Bardales B.M., Garcia A.A., Santos L.M. Interferon beta modulates experimental autoimmune encephalomyelitis by altering the pattern of cytokine secretion. Immunol. Invest. 28:1999;115-126.